ライフサイエンスコーパス: pneumococcal vaccine

1 adults, we assessed the effectiveness of the pneumococcal vaccine.

2 for liver transplantation routinely receive pneumococcal vaccine.

3 obulin loci, XenoMouse, to PPS antigens in a pneumococcal vaccine.

4 ve poor responses to the currently available pneumococcal vaccine.

5 nd both types are included in the polyvalent pneumococcal vaccine.

6 PspAs for inclusion in a broadly protective pneumococcal vaccine.

7 36 patients were vaccinated with a 13-valent pneumococcal vaccine.

8 niae causing bacteremia are contained in the pneumococcal vaccine.

9 89% of PNSP were serotypes in the 23-valent pneumococcal vaccine.

10 12 levels had impaired antibody responses to pneumococcal vaccine.

11 is B; and Haemophilus influenzae type b) and pneumococcal vaccine.

12 t is time for NZ to reconsider its choice of pneumococcal vaccine.

13 accine, and 1.20 (95% CI, 0.94-1.55) for the pneumococcal vaccine.

14 ses to nonadjuvanted TI-2 Ags, including the pneumococcal vaccine.

15 meric subjects generated immune responses to pneumococcal vaccine.

16 frequency has been reduced by the conjugate pneumococcal vaccine.

17 posal of the use of the pilus as a candidate pneumococcal vaccine.

18 complicated the development of an effective pneumococcal vaccine.

19 nt with SLE who had just previously received pneumococcal vaccine.

20 e in the years pre- and post-introduction of pneumococcal vaccine.

21 et initiated vaccination with the conjugated pneumococcal vaccine.

22 care who had been vaccinated with conjugated pneumococcal vaccine.

23 erage as compared to the currently available pneumococcal vaccines.

24 s for the development of more broadly-acting pneumococcal vaccines.

25 city of protein antigens of potential use in pneumococcal vaccines.

26 in the currently available 23- and 7-valent pneumococcal vaccines.

27 HIB-conjugate, tetanus toxoid and 23-valent pneumococcal vaccines.

28 and 10 646 220 (79.5%) had not received any pneumococcal vaccines.

29 are fundamental to assessing the effects of pneumococcal vaccines.

30 improve the effectiveness of next-generation pneumococcal vaccines.

31 P) is essential for evaluating the impact of pneumococcal vaccines.

32 nd data from a recent study on influenza and pneumococcal vaccines.

33 ge is essential for evaluating the impact of pneumococcal vaccines.

34 d adaptive immune responses to influenza and pneumococcal vaccines.

35 lular pertussis, meningococcal conjugate and pneumococcal vaccines.

36 omise for rational design of live-attenuated pneumococcal vaccines.

37 han 90% who strongly recommend influenza and pneumococcal vaccines.

38 nsideration for addition to future conjugate pneumococcal vaccines.

39 hich helped countries access more affordable pneumococcal vaccines.

40 owed by one dose of 23-valent polysaccharide pneumococcal vaccine (23-PS).

41 d by serotypes in the seven-valent conjugate pneumococcal vaccine (71.5% from 1989-1993 and 58.3% fro

42 disease burden after introduction of several pneumococcal vaccines, a UAD-2 assay was developed to de

43 GAVI's Pneumococcal vaccines Accelerated Development and Introd

44 Alaska adults with IPD had an indication for pneumococcal vaccine according to updated vaccination gu

45 reminders for increasing both influenza and pneumococcal vaccine administration.

46 luenza vaccine (adults aged >=18 years), and pneumococcal vaccine (adults aged >=65 years).

47 h significantly increased Ab boosting to the pneumococcal vaccine after both vaccination and infectio

48 Based on our results, revaccination with pneumococcal vaccines after transplantation should be co

49 cination for young children, the efficacy of pneumococcal vaccine against invasive disease, and new i

50 an challenge study to test the efficacy of a pneumococcal vaccine against pneumococcal carriage in Af

51 between serotypes 6A and 6C, the effects of pneumococcal vaccines against serotype 6C are unknown.

52 After residents received pneumococcal vaccine and prophylactic antibiotics, there

53 Increased use of pneumococcal vaccine and recognition of antimicrobial re

54 The timely change in pneumococcal vaccine and subsequent incidence decreases

55 uating risk factors that indicate a need for pneumococcal vaccine and the initiation of annual influe

56 nders have a general inability to respond to pneumococcal vaccine and to determine whether elderly lo

57 is essential for evaluating and formulating pneumococcal vaccines and for informing vaccine policy.

58 ety profile comparable to currently licensed pneumococcal vaccines and generates IgG and functional i

59 is more immunogenic than the polysaccharide pneumococcal vaccines and is 80-100% effective against v

60 whereas the population size benefiting from pneumococcal vaccines and robustness of immunogenic resp

61 ou test, colonoscopy, influenza vaccine, and pneumococcal vaccine) and social risk factor domains, wh

62 Tetanus booster vaccine, pneumococcal vaccine, and intracutaneous skin tests were

63 To address this risk, they receive pneumococcal vaccines, and antibiotic prophylaxis and tr

64 presence of protective titers to tetanus or pneumococcal vaccines, and sustained discontinuation of

65 sure of the protective immunity induced with pneumococcal vaccines, and the absence of a partially cr

66 to hepatitis B, tetanus and diphtheria, and pneumococcal vaccines; and autoantibodies to DNA and thy

67 ectively, these findings present a universal pneumococcal vaccine antigen that remains effective foll

68 entrations to tetanus toxoid, pertussis, and pneumococcal vaccine antigens were higher among 525 HEU

69 The only pneumococcal vaccine approved to date for children young

70 Since pneumococcal vaccines are designed to elicit antibodies

71 Existing pneumococcal vaccines are designed to elicit anticapsule

72 Pneumococcal vaccines are increasingly relevant.

73 core prediction rule in the era of conjugate pneumococcal vaccine as an accurate decision support too

74 ts were enrolled to receive a single dose of pneumococcal vaccine as follows: cohort 1 (n = 350) prev

75 nes at 3, 6, 12, and 24 months and 23-valent pneumococcal vaccine at 12 and 24 months.

76 m can identify not only all the serotypes in pneumococcal vaccines but also most (>90%) of clinical i

77 family to bacterial adherence and identify a pneumococcal vaccine candidate.

78 Pneumococcal vaccines contain serotype 6B but not seroty

79 Pneumococcal vaccines containing protein-conjugated olig

80 Two pneumococcal vaccines containing S. pneumoniae capsular

81 The extensive capsular overlap suggests that pneumococcal vaccines could reduce carriage of oral stre

82 Pneumococcal vaccine coverage of OPSI patients was low o

83 eactive material (CRM197) protein-conjugated pneumococcal vaccine (CV) containing 10 microgram each o

84 that integrating evolutionary thinking into pneumococcal vaccine design will lead to the avoidance o

85 MalX and PrsA could serve as a platform for pneumococcal vaccine development targeting the elderly a

86 x1 PspA is currently under consideration for pneumococcal vaccine development.

87 ponders, revaccination with a double dose of pneumococcal vaccine did not stimulate IgG responses.

88 zae (DTPPHi) vaccine, influenza vaccine, and pneumococcal vaccine, during follow-up.

89 Information concerning sex differences in pneumococcal vaccine effectiveness in adults is scarce.

90 Studies of pneumococcal vaccine efficacy against colonization have

91 serotyping clinical isolates for evaluating pneumococcal vaccine efficacy.

92 y variable, and this should be considered in pneumococcal vaccine evaluations or when capsular polysa

93 ns and lower response rates to influenza and pneumococcal vaccines, even after antiretroviral therapy

94 tolerability, and immunogenicity of V116 in pneumococcal vaccine-experienced adults aged >=50 years.

95 tal C57BL/6 mice immunized with a PC-bearing pneumococcal vaccine expressed increased frequencies of

96 The molecular mechanism of pneumococcal vaccine failure in human immunodeficiency v

97 how promise as components in next-generation pneumococcal vaccine formulations.

98 A whole-cell killed unencapsulated pneumococcal vaccine given by the intranasal route with

99 antly more patients who failed to respond to pneumococcal vaccine had low IgG2 concentrations (p=0.02

100 ized donors, whereas donor immunization with pneumococcal vaccine had no effect on antibody concentra

101 A pneumococcal vaccine has been recommended in the United

102 e introduction of the conjugate seven-valent pneumococcal vaccine has led to the replacement of vacci

103 A new generation of pneumococcal vaccines has been developed, linking the ca

104 The introduction of serotype-specific pneumococcal vaccines has reduced the burden of disease

105 of different pneumococcal serotypes as newer pneumococcal vaccines have been introduced.

106 Although unconjugated polysaccharide pneumococcal vaccines have demonstrated effectiveness in

107 Capsule-targeted pneumococcal vaccines have likely contributed to increas

108 Currently, published trials of conjugated pneumococcal vaccines have shown the effectiveness and s

109 Conjugate and polysaccharide pneumococcal vaccines have similar efficacy against inva

110 of the MenACWY vaccine included receipt of a pneumococcal vaccine (hazard ratio [HR], 23.03; 95% CI,

111 aureus colonization among children receiving pneumococcal vaccine implicate Streptococcus pneumoniae

112 betic patients who received a single dose of pneumococcal vaccine improved from 24% in 1987 to 1988 t

113 he highly effective introduction of the PCV7 pneumococcal vaccine in 2000 in the United States(2,3) p

114 vered prior to introduction of the conjugate pneumococcal vaccine in 2000; the earliest isolate was r

115 n CSF leakage had been vaccinated (23-valent pneumococcal vaccine in 9 patients, meningococcal serogr

116 reason for the deficient immune response to pneumococcal vaccine in aged mice is a quantitative defe

117 cine significantly reduces rates of invasive pneumococcal vaccine in healthy and HIV-infected childre

118 es suggest a potential role for the 7-valent pneumococcal vaccine in HIV-infected adults.

119 sis and improve the clinical efficacy of the pneumococcal vaccine in patients with low vitamin B12 le

120 studied the efficacy of a 7-valent conjugate pneumococcal vaccine in predominantly HIV-infected Malaw

121 Our data support the introduction of pneumococcal vaccine in sub-Saharan Africa.

122 this approach to improve the performance of pneumococcal vaccine in the elderly, we evaluated pneumo

123 fficacy of the currently available 23-valent pneumococcal vaccine in the growing population of adults

124 per dose, purchase and accelerated uptake of pneumococcal vaccine in the world's poorest countries is

125 of controlled clinical evaluations of newer pneumococcal vaccines in all high-risk groups for whom p

126 is suggested by the impaired IgG response to pneumococcal vaccines in some IgA-deficient patients.

127 erstand progression to disease and impact of pneumococcal vaccines in the elderly.

128 Many lots of pneumococcal vaccines, including the heptavalent conjuga

129 llows saccharide quantitation in multivalent pneumococcal vaccine intermediates and final drug produc

130 >= 55 years old (y), >= 4-years after infant-pneumococcal vaccine introduction and before 2020, and V

131 ratory syncytial virus (RSV) seasons, before pneumococcal vaccine introduction.

132 ae and S. aureus disease incidence following pneumococcal vaccine introduction.

133 ecognized in nursing homes, and wider use of pneumococcal vaccine is important to prevent institution

134 Because pneumococcal vaccine is routinely given to HIV-1-infecte

135 The Advanced Market Commitment for pneumococcal vaccines is a so-called pull mechanism that

136 Haemophilus influenzae type b conjugate, and pneumococcal vaccines is included in this first of two a

137 Pneumococcal vaccine may be most protective when it is a

138 he possibilities that whole-cell inactivated pneumococcal vaccines may confer cross-protection to mul

139 tion of this mutant pneumolysin into current pneumococcal vaccines may increase their efficacy.

140 we show that in low/middle-income countries, pneumococcal vaccines may prevent a substantial proporti

141 Pneumococcal vaccine-naive mother-child dyads in South A

142 The long-term immunogenicity of PCV13 in pneumococcal vaccine-naive older adults was investigated

143 Pneumococcal vaccines need to include more serotypes to

144 nd the impact of vaccination with conjugated pneumococcal vaccine, on the occurrence of serious bacte

145 ough they were found to be associated to the pneumococcal vaccine only in previous analyses.

146 cells from mice vaccinated with a 23-valent pneumococcal vaccine or a PPS 3-bovine serum albumin con

147 enza vaccine (OR, 0.81 [95% CI, 0.80-0.83]), pneumococcal vaccine (OR, 0.80 [95% CI, 0.77-0.83]), and

148 vaccine or a control (meningococcal vaccine, pneumococcal vaccine, or placebo).

149 uenza vaccine: OR, 0.44 [95% CI, 0.41-0.47]; pneumococcal vaccine: OR, 0.30 [95% CI, 0.25-0.38]; colo

150 uenza vaccine: OR, 0.71 [95% CI, 0.67-0.74]; pneumococcal vaccine: OR, 0.68 [95% CI, 0.63-0.75]; colo

151 With all serotyped IPD isolates covered by pneumococcal vaccines, our study provides additional arg

152 Heptavalent protein-conjugate pneumococcal vaccine (PCPV-7) was then administered, and

153 Despite the demonstrated impact of pneumococcal vaccine (PCV) implementation on otitis medi

154 We studied PPV, protein-conjugate pneumococcal vaccine (PCV), and immunologic "priming" wi

155 mmunological efficacy of 13-valent conjugate pneumococcal vaccine (PCV13) followed by a 23-valent pol

156 ultaneous vaccination with TIV and 13-valent pneumococcal vaccine (PCV13) in children who were 6 to 2

157 rage of serotypes in the 13-valent conjugate pneumococcal vaccine (PCV13) was high, some non-PCV13-em

158 The 13-valent pneumococcal vaccine (PCV13) was introduced for U.S. chi

159 The 13-valent pneumococcal vaccine (PCV13) was introduced for US child

160 (Hib-TT) vaccine at 2-3-4 months, 13-valent pneumococcal vaccine (PCV13, CRM-conjugated) at 2-4 mont

161 monia following introduction of the 7-valent pneumococcal vaccine (PCV7) are sparse, especially in ad

162 The introduction of the 7-valent conjugate pneumococcal vaccine (PCV7) in children may result in se

163 000, the year of 7-valent protein-conjugated pneumococcal vaccine (PCV7) introduction (139 versus 55

164 ne (TIV; delivered to mothers) plus 7-valent pneumococcal vaccine (PCV7; delivered to infants) was hi

165 even-valent polysaccharide protein conjugate pneumococcal vaccine (PnCRM7) against such disease.

166 to be used in preparation of the polyvalent pneumococcal vaccine PNEUMOVAX 23.

167 continue to have an important role in adult pneumococcal vaccine policy, including the possibility o

168 llection to discern causes and inform future pneumococcal vaccine policy.

169 ts had vigorous immune responses to selected pneumococcal vaccine polysaccharides, a subset of elderl

170 s to all V116 serotypes, regardless of prior pneumococcal vaccine received.

171 Influenza and pneumococcal vaccines reduce secondary infections within

172 ring pregnancy was associated with increased pneumococcal vaccine-related serotype carriage in infant

173 etween Tdap vaccination during pregnancy and pneumococcal vaccine-related serotype carriage in infant

174 valuated the effect of age and CMV status on pneumococcal vaccine responses in 348 individuals aged 5

175 not directly responsible for the decline in pneumococcal vaccine responses seen with age but suggest

176 f sera from mice vaccinated with a 23-valent pneumococcal vaccine revealed that they produced serotyp

177 mmendations, including PCV15/20 within adult pneumococcal vaccine series, may substantially reduce LR

178 use and high coverage of conjugate vaccines, pneumococcal vaccine serotypes and H. influenzae type b

179 The proportion of pneumococcal vaccine serotypes causing meningitis decrea

180 es, its impact on nasopharyngeal carriage of pneumococcal vaccine serotypes remains unclear.

181 Immediate replacement of pneumococcal vaccine serotypes with non-vaccine serotype

182 Patients with standing orders received a pneumococcal vaccine significantly more often (51%) than

183 Pneumococcal vaccine significantly reduces rates of inva

184 than 5 times as likely to have received the pneumococcal vaccine than the control group (44/221 [19.

185 Development of a pneumococcal vaccine that is immunogenic in young childr

186 or the development of a serotype-independent pneumococcal vaccine that would reduce pneumococcal carr

187 l Microbiology underscore the limitations of pneumococcal vaccines that target the polysaccharide cap

188 ions for the long-term efficacy of conjugate pneumococcal vaccines that will protect against only a l

189 ral recommended guidelines for administering pneumococcal vaccine to HIV-infected persons.

190 hese data support recommendations to provide pneumococcal vaccine to persons in these at-risk groups

191 re obtained from pediatric participants in a pneumococcal vaccine trial.

192 art failure, lung disease, and influenza and pneumococcal vaccine uptake, except aTIV homes housed fe

193 art failure, lung disease, and influenza and pneumococcal vaccine uptake, except aTIV homes housed fe

194 could help us predict the effects of future pneumococcal vaccine use in children on disease rates in

195 athogen as Haemophilus influenzae type b and pneumococcal vaccine use in Mali has diminished invasive

196 ucture of antibodies elicited by a 23-valent pneumococcal vaccine was analyzed.

197 Receipt of the pneumococcal vaccine was associated with a significant r

198 rt of men aged 45 years or older, receipt of pneumococcal vaccine was not associated with subsequent

199 protective antigens were deleted, the killed pneumococcal vaccine was still protective.

200 HIV-infected men immunized with pneumococcal vaccine were classified as high- or low-lev

201 en (KLH) and T cell-independent responses to pneumococcal vaccine were decreased, but many patients w

202 bulin G (IgG) subclass antibody responses to pneumococcal vaccines were determined for human subjects

203 lular and humoral responses to influenza and pneumococcal vaccines were evaluated in 51 chronic phase

204 Currently available pneumococcal vaccines were examined for contamination by

205 iotics, and development and use of effective pneumococcal vaccines will be required to treat and prev

206 re 4 times more likely to have discussed the pneumococcal vaccine with their physicians than patients

207 Development of new pneumococcal vaccines with expanded serotype coverage ha

208 Pneumococcal vaccines with more robust and sustained imm

209 of these patients had received the 23-valent pneumococcal vaccine within the previous 5 years.